Should I buy or sell Hepion Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hepion Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HEPA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HEPA, but not buy additional shares or sell existing shares. View HEPA analyst ratings or view top-rated stocks .

How have HEPA shares performed in 2024?

Hepion Pharmaceuticals' stock was trading at $3.24 at the beginning of the year. Since then, HEPA shares have decreased by 32.7% and is now trading at $2.18. View the best growth stocks for 2024 here .

Are investors shorting Hepion Pharmaceuticals?

Hepion Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 62,800 shares, an increase of 11.0% from the March 15th total of 56,600 shares. Based on an average daily trading volume, of 76,600 shares, the short-interest ratio is presently 0.8 days. Currently, 1.5% of the shares of the stock are sold short. View Hepion Pharmaceuticals' Short Interest .

When is Hepion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our HEPA earnings forecast .

How were Hepion Pharmaceuticals' earnings last quarter?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) released its earnings results on Sunday, November, 15th. The company reported ($13.80) earnings per share for the quarter, missing analysts' consensus estimates of ($10.20) by $3.60.

When did Hepion Pharmaceuticals' stock split?

Shares of Hepion Pharmaceuticals reverse split on the morning of Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Hepion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hepion Pharmaceuticals investors own include Bausch Health Companies (BHC) , Axsome Therapeutics (AXSM) , Archrock (AROC) , Alector (ALEC) , AIM ImmunoTech (AIM) , Applied Genetic Technologies (AGTC) , Abbott Laboratories (ABT) and Ambev (ABEV) .

How do I buy shares of Hepion Pharmaceuticals?

Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HEPA

Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free HEPA Stock Alerts

$2.14

+0.03 (+1.42%)

(As of 12:47 PM ET)

Compare

Today's Range: $2.12
▼
$2.18
50-Day Range: $1.52
▼
$3.17
52-Week Range: $1.49
▼
$20.66

Volume: 16,747 shs
Average Volume: 69,858 shs
Market Capitalization: $11.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Hepion Pharmaceuticals alerts:

Hepion Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.62
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($11.43) to ($17.20) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.14 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Hepion Pharmaceuticals.

3.0

Short Interest

Percentage of Shares Shorted
1.47% of the float of Hepion Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Hepion Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Hepion Pharmaceuticals has recently increased by 10.95%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Hepion Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Hepion Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HEPA.

2.0

News and Social Media Coverage

News Sentiment
Hepion Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Hepion Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for HEPA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hepion Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.95% of the stock of Hepion Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 17.24% of the stock of Hepion Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Hepion Pharmaceuticals are expected to decrease in the coming year, from ($11.43) to ($17.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hepion Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hepion Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Hepion Pharmaceuticals has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Hepion Pharmaceuticals Stock (NASDAQ:HEPA)

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

HEPA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HEPA Stock News Headlines

April 17, 2024 | msn.com

HEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023

April 15, 2024 | americanbankingnews.com

Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Expands By 11.0%

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 14, 2024 | morningstar.com

Hepion Pharmaceuticals Inc HEPA

March 24, 2024 | investing.com

Hepion Pharmaceuticals Inc (HEPA)

March 6, 2024 | globenewswire.com

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

February 16, 2024 | finance.yahoo.com

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

February 16, 2024 | globenewswire.com

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 3, 2024 | finance.yahoo.com

Hepion Pharmaceuticals to Present at NASH-TAG 2024

December 7, 2023 | finanznachrichten.de

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

December 7, 2023 | realmoney.thestreet.com

Hepion Pharmaceuticals downgraded to Hold from Buy at Brookline

December 7, 2023 | marketwatch.com

Hepion Sets Restructuring; To Explore Strategic Options

December 7, 2023 | finance.yahoo.com

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

November 28, 2023 | finance.yahoo.com

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

November 28, 2023 | msn.com

Hepion Pharmaceuticals says Wijngaard buys 5K shares in co

November 13, 2023 | finance.yahoo.com

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

November 10, 2023 | benzinga.com

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

November 10, 2023 | finance.yahoo.com

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat

October 31, 2023 | money.usnews.com

GSK Signs $1 Billion Deal for Exclusive License to J&J's Hepatitis B Therapy

October 25, 2023 | finanznachrichten.de

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

October 25, 2023 | finance.yahoo.com

Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

September 29, 2023 | msn.com

Hepion to sell $5M in shares through registered direct offering

September 29, 2023 | finance.yahoo.com

Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules

September 21, 2023 | finance.yahoo.com

Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference

September 21, 2023 | finance.yahoo.com

New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program

September 19, 2023 | finance.yahoo.com

Here's Why Hepion Pharmaceuticals (NASDAQ:HEPA) Must Use Its Cash Wisely

See More Headlines

Receive HEPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2020
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:HEPA
CUSIP: N/A
CIK: 1583771
Web: www.hepionpharma.com
Phone: (732) 902-4000
Fax: 732-902-4100
Employees: 25
Year Founded: 2013

Profitability

EPS (Most Recent Fiscal Year): ($12.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,200,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -145.58%
Return on Assets: -104.36%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.32
Quick Ratio: 3.32

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.64 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 5,470,000
Free Float: 4,253,000
Market Cap: $11.92 million
Optionable: No Data
Beta: 1.54

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. John T. Cavan (Age 66)
Interim CEO & CFO
Comp: $495.33k
Sharen Pyatetskaya
Director of Investor Relations
Dr. John Z. Sullivan-Bolyai (Age 76)
Part-Time Consultant
Dr. Stephen A. Harrison FACP
M.D., Scientific Advisory Board Chair & Consultant Medical Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HEPA Stock Analysis - Frequently Asked Questions

Should I buy or sell Hepion Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hepion Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HEPA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HEPA, but not buy additional shares or sell existing shares.
View HEPA analyst ratings or view top-rated stocks.
How have HEPA shares performed in 2024?: Hepion Pharmaceuticals' stock was trading at $3.24 at the beginning of the year. Since then, HEPA shares have decreased by 32.7% and is now trading at $2.18.
View the best growth stocks for 2024 here.
Are investors shorting Hepion Pharmaceuticals?: Hepion Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 62,800 shares, an increase of 11.0% from the March 15th total of 56,600 shares. Based on an average daily trading volume, of 76,600 shares, the short-interest ratio is presently 0.8 days. Currently, 1.5% of the shares of the stock are sold short.
View Hepion Pharmaceuticals' Short Interest.
When is Hepion Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our HEPA earnings forecast.

How were Hepion Pharmaceuticals' earnings last quarter?: Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) released its earnings results on Sunday, November, 15th. The company reported ($13.80) earnings per share for the quarter, missing analysts' consensus estimates of ($10.20) by $3.60.
When did Hepion Pharmaceuticals' stock split?: Shares of Hepion Pharmaceuticals reverse split on the morning of Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Hepion Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hepion Pharmaceuticals investors own include Bausch Health Companies (BHC), Axsome Therapeutics (AXSM), Archrock (AROC), Alector (ALEC), AIM ImmunoTech (AIM), Applied Genetic Technologies (AGTC), Abbott Laboratories (ABT) and Ambev (ABEV).
How do I buy shares of Hepion Pharmaceuticals?: Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HEPA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis

Hepion Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Hepion Pharmaceuticals Stock (NASDAQ:HEPA)

HEPA Stock Price History

HEPA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

HEPA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™